Table 2.
MLR | Model 1 | Model 2 | Model 3 | |||
---|---|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
Cox model | ||||||
Lowest tertile | 1.0 | 1.0 | 1.0 | |||
Middle tertile | 1.24 (1.13-2.34) | 0.013 | 1.19 (1.09-2.46) | 0.030 | 1.13 (1.07-2.55) | 0.037 |
Highest tertile | 1.64 (1.16-2.32) | 0.005 | 1.56 (1.15-2.44) | 0.009 | 1.45 (1.13-2.51) | 0.016 |
Competing risk∗ | ||||||
Lowest tertile | 1.0 | 1.0 | 1.0 | |||
Middle tertile | 1.22 (1.11-2.33) | 0.014 | 1.16 (1.08-2.40) | 0.032 | 1.10 (1.06-2.50) | 0.039 |
Highest tertile | 1.61 (1.15-2.30) | 0.007 | 1.52 (1.14-2.43) | 0.011 | 1.39 (1.10-2.47) | 0.021 |
Competing risk# | ||||||
Lowest tertile | 1.0 | 1.0 | 1.0 | |||
Middle tertile | 1.18 (1.09-2.40) | 0.017 | 1.14 (1.07-2.46) | 0.037 | 1.09 (1.05-2.56) | 0.040 |
Highest tertile | 1.57 (1.13-2.36) | 0.010 | 1.48 (1.11-2.49) | 0.018 | 1.37 (1.09-2.54) | 0.026 |
∗All-cause mortality as a competing risk. #Kidney transplantation or hemodialysis as a competing event risk. Model 1: unadjusted. Model 2: adjusted for age, sex, CCI, current smoking, current drinking, ACEI/ARB use, β-blocker use, and statin use. Model 3: model 2 adjusted for serum albumin, total cholesterol, triglycerides, LDL, HDL, serum uric acid, hs-CRP, NT-pro-BNP, and eGFR. CVD: cardiovascular disease; MLR: monocyte-to-lymphocyte ratio; CCI: Charlson comorbidity index; ACEI/ARB: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; HDL: high-density lipoprotein; hs-CRP: high-sensitivity C-reactive protein; NT-pro-BNP: N-terminal probrain natriuretic peptide; eGFR: estimated glomerular filtration rate.